Deepak Gupta

US Patent:

7902073, Mar 8, 2011

Filed:

Dec 14, 2006

Appl. No.:

11/610953

Inventors:

Ji Soo Kim - Pleasanton CA, US
Sangheon Lee - Dublin CA, US
Deepak K. Gupta - Fremont CA, US
S. M. Reza Sadjadi - Saratoga CA, US

Assignee:

Lam Research Corporation - Fremont CA

International Classification:

H01L 21/311

US Classification:

438694, 438654, 438689, 438781, 438784

Abstract:

A method for etching features in an etch layer disposed below a mask on a process wafer is provided. A hydrocarbon based glue layer is deposited. The etch layer on the process wafer is etched with at least one cycle, wherein each cycle comprises depositing a hydrofluorocarbon layer over the mask and on the hydrocarbon based glue layer, wherein the hydrocarbon based glue layer increases adhesion of the hydrofluorocarbon layer and etching the etch layer.

US Patent:

20020169135, Nov 14, 2002

Filed:

Nov 7, 2001

Appl. No.:

10/007352

Inventors:

Arthur Pardee - Cambridge MA, US
Kenneth Anderson - Wellesley MA, US
Deepak Gupta - Norwood MA, US
Chiang Li - West Roxbury MA, US
Youzhi Li - Dedham MA, US

International Classification:

A61K031/7048
A61K031/704
A61K031/4745

US Classification:

514/027000, 514/034000, 514/283000, 514/449000, 514/365000, 514/682000

Abstract:

Multiple myeloma and other hematologic tumors and/or malignancies can be treated by administration of a G1 and/or S phase drug, which is preferably -lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel. This combination of the G1 and/or S phase drug with the G2/M phase drug results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in multiple myeloma cells. The invention includes methods of treating multiple myeloma by administering the combination of the G1 and/or S phase drug and the G2/M phase drug, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.

US Patent:

20030036515, Feb 20, 2003

Filed:

Jul 31, 2002

Appl. No.:

10/209388

Inventors:

Arthur Pardee - Cambridge MA, US
Kenneth Anderson - Wellesley MA, US
Deepak Gupta - Westborough MA, US
Chiang Li - West Roxbury MA, US
Youzhi Li - Dedham MA, US

International Classification:

A61K031/7048
A61K031/704
A61K031/4745
A61K031/427
A61K031/337
A61K031/12

US Classification:

514/027000, 514/449000, 514/283000, 514/375000, 514/034000, 514/680000

Abstract:

Multiple myeloma and other hematologic tumors and/or malignancies can be treated by administration of a G1 and/or S phase drug, which is preferably -lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel. This combination of the G1 and/or S phase drug with the G2/M phase drug results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in multiple myeloma cells. The invention includes methods of treating multiple myeloma by administering the combination of the G1 and/or S phase drug and the G2/M phase drug, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.

US Patent:

20060183793, Aug 17, 2006

Filed:

Dec 21, 2005

Appl. No.:

11/315430

Inventors:

Arthur Pardee - Cambridge MA, US
Kenneth Anderson - Wellesley MA, US
Deepak Gupta - Westborough MA, US
Chiang Li - West Roxbury MA, US
Youzhi Li - Dedham MA, US

International Classification:

A61K 31/353

US Classification:

514454000

Abstract:

Multiple myeloma and other hematologic tumors and/or malignancies can be treated by administration of a G1 and/or S phase drug, which is preferably β-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel. This combination of the G1 and/or S phase drug with the G2/M phase drug results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in multiple myeloma cells. The invention includes methods of treating multiple myeloma by administering the combination of the G1 and/or S phase drug and the G2/M phase drug, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.

US Patent:

20110244566, Oct 6, 2011

Filed:

Feb 1, 2011

Appl. No.:

12/931476

Inventors:

Joseph Wu - Palo Alto CA, US
Michael T. Longaker - Stanford CA, US
Mark A. Kay - Stanford CA, US
Ning Sung - Stanford CA, US
FangJun Jia - Stanford CA, US
Zhi-Ying Chen - Shenzhen, CN
Nicholas Panetta - Pittsburg PA, US
Deepak Gupta - Stanford CA, US

International Classification:

C12N 5/074
C12N 15/63

US Classification:

435366, 435377, 4353201

Abstract:

Human somatic cells are reprogrammed to become induced pluripotent stem cells (iPS cells) by the introduction of a minicircle DNA vector. Cells of interest include adipose stem cells.

US Patent:

20220283813, Sep 8, 2022

Filed:

Jun 26, 2021

Appl. No.:

17/359534

Inventors:

- Santa Clara CA, US
H. Peter Anvin - San Jose CA, US
Vedvyas Shanbhogue - Austin TX, US
Deepak Gupta - Portland OR, US

International Classification:

G06F 9/30

Abstract:

Techniques for flexible return and event delivery are described. As an example, an exemplary apparatus includes decoder circuitry to decode a single instruction, the single instruction to include a field for an opcode; and execution circuitry to execute the decoded single instruction according to the opcode to cause a return from an event handler while staying in a most privileged level and establish a return context that was in effect before event delivery.

US Patent:

20150184131, Jul 2, 2015

Filed:

Jan 6, 2015

Appl. No.:

14/590802

Inventors:

- Palo Alto CA, US
Michael T. Longaker - Stanford CA, US
Mark A. Kay - Los Altos CA, US
Ning Sung - Stanford CA, US
FangJun Jia - Stanford CA, US
Zhi-Ying Chen - Shenzhen, CN
Nicholas Panetta - PIttsburgh PA, US
Deepak Gupta - Stanford CA, US

International Classification:

C12N 5/074
C12N 15/85

Abstract:

Human somatic cells are reprogrammed to become induced pluripotent stem cells (iPS cells) by the introduction of a minicircle DNA vector. Cells of interest include adipose stem cells.